Employers dropping GLP 1 coverage push weight loss costs onto workers

Only 53% of US employers now pay for GLP 1 drugs prescribed for weight loss, down from 57% in 2025, according to a WTW survey reported on October 30. The figure shows employers dropping GLP 1 coverage for the first time since prescribing for weight loss surged about three years ago, and it moves more of the cost from health plans toward workers. Diabetes cover mostly stays in place. What replaces weight loss cover is less settled: employer subsidies, outside discount routes, or nothing at all.

What the WTW survey found

The benefits consultancy surveyed nearly 500 companies, according to a Briefs Finance summary of the findings. Its headline finding: 53% of US employers pay for GLP 1 medicines used for weight loss this year, compared with 57% in 2025. That four point slide is the first drop WTW has recorded since uptake of the drugs for weight loss accelerated. The warning sign for the next plan year is larger. Among employers that still pay, 30% told WTW they are weighing whether to end the benefit. Respondents gave three reasons: higher costs, strong demand from workers, and trouble proving that the spending pays off. Readers who followed our earlier report on the survey will recognize the headline number, but the pressure behind it keeps building.

Several large names have already stopped paying for the drugs for weight loss. The report lists Lowe's, PepsiCo, PricewaterhouseCoopers, Starbucks and Cigna among them. About 11% of Americans use GLP 1 drugs for weight loss, the report says, so each exclusion can touch a large share of a workforce. Several basic questions remain open. The published figures do not say how many workers have lost cover, which brands are affected most, or when each exclusion takes effect. Peptide Town has not seen the full WTW report, so the numbers below come from the reported summary. They set the survey figures beside the cost estimates that employers cite when they explain their decisions, which helps show why plan sponsors are under pressure from both sides at once.

Why employer health plan costs drive the cuts

Price is the main pressure on employers. The Employee Benefit Research Institute estimates that a 30 day supply of a GLP 1 drug costs $617 to $766, and that adding the drugs can raise monthly premiums by up to 14%. Those estimates land on top of employer health plan costs that were already climbing. KFF reports that the average family health plan rose 5% this year to $28,303, with employers paying 73% of that amount. By our arithmetic, that leaves the employer share of an average family plan at roughly $20,700 a year before any decision about weight loss drugs. Drug spending has been one of the forces pushing plan costs higher in recent years, the report says, and GLP 1 medicines sit near the top of that list for many sponsors.

The Employee Benefit Research Institute estimates that a 30 day supply of a GLP 1 drug costs $617 to $766, and that adding the drugs can raise monthly premiums by up to 14%.

Employers are answering with several tools at once. The report describes higher worker premiums and copays, less cover for dependents, and an end to paying for weight loss drugs. In a message to staff, PepsiCo called GLP 1 drugs "one of the fastest-growing costs" it carries, and said the change keeps its health program "sustainable and affordable for all PepsiCo employees." Cigna said clinical leaders advised it before the drugs came off its plans, and it still offers weight loss coaching. Jeff Levin-Scherz put the tension plainly: "These are great drugs, and they have huge clinical benefits, but the costs are not sustainable." For workers, the result of employers dropping GLP 1 coverage is the same in each case: a bigger share of the bill moves to the household budget.

Workers push back on lost GLP 1 weight loss coverage

The cuts have not gone quietly. Bloomberg Businessweek reported in September that staff at Cigna, PepsiCo and several municipal governments answered the cuts by signing petitions, filing complaints with state labor officials and running public campaigns. The report does not say whether any complaint has changed a plan decision, and no regulator has said it will act on the filings. Public employers are part of this fight, and their benefit choices are debated in the open. That pressure helps explain why the loss of GLP 1 weight loss coverage has become a labor issue as well as a benefits issue. Workers who started treatment under one plan year can find the drug excluded in the next, often with no covered alternative for weight loss.

For patients, the practical question is what happens to treatment already under way. The report does not say how many workers stopped their medicine after losing cover, or how many switched to paying cash. Readers facing this change should read their 2027 plan documents during open enrollment, ask whether a diabetes diagnosis changes their status, and talk with their prescriber before stopping any drug. Some people who lose cover may be tempted by cheaper copies sold online. Compounded and gray market products are not FDA approved, their makers do not go through the same review as approved brands, and quality can vary from batch to batch. As more employers dropping GLP 1 coverage push workers toward cash routes, that risk grows, which is why legitimate pharmacies and licensed prescribers remain the safer path to care.

Drugmaker direct programs and diabetes cover fill some gaps

Not every employer is walking away completely. Some are trying a middle path, according to Mike Pasterick of the consultancy Aon. In his account, the employer pays part of the price, and the worker fills the prescription at a discount from a telehealth provider or from drugmaker direct programs run by Novo Nordisk and Eli Lilly. "It still provides that choice, but it kind of takes the cost burden off of the employer," he said. Similar employer funded routes outside the plan have appeared in recent weeks. GLP 1 diabetes coverage also largely remains, even where weight loss funding ends. Most plans still pay when the drugs treat diabetes, the report says, an approach that matches Walmart's 2027 diabetes only design. Subsidy sizes, worker costs and enrollment numbers were not reported.

Lilly says the pullback will not dent its totals much. On their earnings call, Eli Lilly executives predicted that total coverage for their medicines would stay roughly level through 2027, despite exits by some employers. "Obviously, there's been noise around a number of employers opting out of coverage," said Ilya Yuffa, Lilly's US chief. He added that the company is having "positive discussions" with some employers and expects Medicaid and Medicare to deliver larger coverage gains in 2027. That is a company forecast, not a measured result. Gains in public plans would not restore cover for a worker whose employer has dropped it. Whether the new subsidy models keep treatment affordable for those workers depends on prices and terms that no company has yet published in full.

Conclusion

The WTW figures show employers dropping GLP 1 coverage for weight loss for the first time, with 30% of remaining funders weighing an exit. Costs, demand and weak proof of savings drive the shift. Diabetes cover mostly holds, and some employers are testing subsidies through outside channels, but their terms are not public. Workers should check 2027 plan details early and plan any change of treatment with a prescriber.